These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 22653658

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A.
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis.
    Kantengwa S, Weber MS, Juillard C, Benkhoucha M, Fellay B, Zamvil SS, Gougeon ML, Chofflon M, Lalive PH.
    J Neuroimmunol; 2007 Apr; 185(1-2):123-9. PubMed ID: 17306890
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M, Miravalle A, Vollmer T.
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study.
    Farina C, Wagenpfeil S, Hohlfeld R.
    J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101
    [Abstract] [Full Text] [Related]

  • 30. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
    Karussis D, Teitelbaum D, Sicsic C, Brenner T, AC001 multi-center Israeli study group.
    J Neuroimmunol; 2010 Mar 30; 220(1-2):125-30. PubMed ID: 20153903
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.
    Putheti P, Pettersson A, Soderstrom M, Link H, Huang YM.
    J Clin Immunol; 2004 Mar 30; 24(2):155-61. PubMed ID: 15024182
    [Abstract] [Full Text] [Related]

  • 33. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, Schadendorf D, Croockewit A, Blokx WA, Van Rossum MM, Kwok WW, Adema GJ, Punt CJ, Figdor CG.
    Cancer Res; 2013 Jan 01; 73(1):19-29. PubMed ID: 23087058
    [Abstract] [Full Text] [Related]

  • 34. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla A, Karkare SU, Balderston McGuiness C, Korn JR.
    Curr Med Res Opin; 2013 Dec 01; 29(12):1647-56. PubMed ID: 24059944
    [Abstract] [Full Text] [Related]

  • 35. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.
    Haas J, Korporal M, Balint B, Fritzsching B, Schwarz A, Wildemann B.
    J Neuroimmunol; 2009 Nov 30; 216(1-2):113-7. PubMed ID: 19646767
    [Abstract] [Full Text] [Related]

  • 36. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
    Michałowska-Wender G, Losy J, Wender M, Januszkiewicz-Lewandowska D, Nowak J.
    Pol J Pharmacol; 2003 Nov 30; 55(5):877-80. PubMed ID: 14704481
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
    Ragheb S, Abramczyk S, Lisak D, Lisak R.
    Mult Scler; 2001 Feb 30; 7(1):43-7. PubMed ID: 11321193
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.